(via TheNewswire)
The Corporation is proposing to issue up to 3,125,000 units of the Corporation (“Units”) under the private placement at a price of
The Corporation intends to complete the Offering pursuant to various prospectus exemptions and a portion of the Units will be offered to persons resident in
Under the Existing Shareholder Exemptions, existing shareholders resident in
In the event that aggregate subscriptions for Units under the Offering exceed the maximum number of securities to be distributed, then Units will be sold to qualifying subscribers on apro ratabasis based on the number of Units subscribed for.
Insiders may participate in the Offering. All securities issued in connection with the Offering will be subject to a statutory hold period expiring four months and one day after closing of the Offering. Any participation by insiders in the Offering will constitute a related party transaction under Multilateral Instrument 61-101 -Protection of Minority Security Holders in Special Transactionsbut is expected to be exempt from the formal valuation and minority shareholder approval requirements of that instrument.
The Offering may include finder’s fees commission’s payable in cash and/or securities and is subject to approval of the
Assuming the maximum offering is completed, 100% of the net proceeds are expected to be used to fund the Corporation’s first in-human clinical trials, expected to commence in Q1 2024, and for ongoing research and development. Although the Corporation intends to use the proceeds of the offering as described above, the actual allocation of proceeds may vary from the uses set out above, depending upon future operations, events or opportunities.
As at the date of this press release, there is no material fact or material change related to the Corporation which has not been generally disclosed.
About
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dean Burns
President and CEO Director
(817) 874-7564 (778) 347-2500
Neither the
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the clinical trial program outlined above and that it will be conducted as expected. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source